<![CDATA[Biotek-snakken — August 2022]]>Solgte i 47….genkøber HVIS den kommer ned i 37-38

]]>https://dev.proinvestor.com/forum/topic/401422/biotek-snakken-august-2022RSS for NodeSat, 06 Jun 2026 22:17:42 GMTMon, 01 Aug 2022 05:20:27 GMT60<![CDATA[Reply to Biotek-snakken — August 2022 on Sat, 27 Aug 2022 08:20:33 GMT]]>Trancript fra Q&A med CEO Adam Stensberg/Zealand Pharma Q2 afholdt i går kl. 15. https://www.proinvestor.com/ir/q-and-a/dk

]]>https://dev.proinvestor.com/forum/post/8064969https://dev.proinvestor.com/forum/post/8064969Sat, 27 Aug 2022 08:20:33 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Sat, 27 Aug 2022 05:45:31 GMT]]>Biotech Stocks Facing FDA Decision In September https://www.proinvestor.com/investornyt/871985/biotech-stocks-facing-fda-decision-in-september

]]>https://dev.proinvestor.com/forum/post/8064966https://dev.proinvestor.com/forum/post/8064966Sat, 27 Aug 2022 05:45:31 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Fri, 26 Aug 2022 18:34:25 GMT]]>Mød Genmab A/S Vice President, Head of Investor Relations Andrew Carlsen i en online Q&A session om selskabet og Q2 rapporten mandag d. 29. August kl. 15.00.
Moderator: Helge Larsen.

Spørgsmål skal stilles på forhånd på engelsk i Q&A chatten. Deadline mandag kl. 12.

Tilmelding på link.

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/8064964https://dev.proinvestor.com/forum/post/8064964Fri, 26 Aug 2022 18:34:25 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Fri, 26 Aug 2022 07:49:09 GMT]]>“We have legacy partnerships and future milestones coming to us, which we could monetize with someone else for upfront liquidity and pass those future payments on to a financing partner,” he adds. “We hope to announce something about that later this year.”

]]>https://dev.proinvestor.com/forum/post/8064965https://dev.proinvestor.com/forum/post/8064965Fri, 26 Aug 2022 07:49:09 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Fri, 26 Aug 2022 06:15:32 GMT]]>
Link Preview Image
Zymeworks targeting cancer with next-gen multifunctional biotherapeutics - BioTuesdays

Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.

favicon

BioTuesdays (biotuesdays.com)

]]>https://dev.proinvestor.com/forum/post/8064968https://dev.proinvestor.com/forum/post/8064968Fri, 26 Aug 2022 06:15:32 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Fri, 26 Aug 2022 06:15:30 GMT]]>Lidt Zymeworks:

]]>https://dev.proinvestor.com/forum/post/8064961https://dev.proinvestor.com/forum/post/8064961Fri, 26 Aug 2022 06:15:30 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Thu, 25 Aug 2022 14:31:41 GMT]]>InvestorBAVA: ExpreS2ion er blevet lidt mere specifikke for breast cancer vaccinen i halvårsrapporten. Nu siger de filing af clinical study H2 2023 og start 2024. Håber, at de lykkes med vaccinen. In vivo resultaterne i mus ser i hvert fald særdeles lovende ud.

]]>https://dev.proinvestor.com/forum/post/8064959https://dev.proinvestor.com/forum/post/8064959Thu, 25 Aug 2022 14:31:41 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Thu, 25 Aug 2022 05:56:08 GMT]]>2cureX - interim report for H1 2022 https://www.proinvestor.com/boards/105587

]]>https://dev.proinvestor.com/forum/post/8064963https://dev.proinvestor.com/forum/post/8064963Thu, 25 Aug 2022 05:56:08 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Wed, 24 Aug 2022 09:01:44 GMT]]>STENOCARE starting sales in Australia https://www.proinvestor.com/boards/105553

]]>https://dev.proinvestor.com/forum/post/8064962https://dev.proinvestor.com/forum/post/8064962Wed, 24 Aug 2022 09:01:44 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 22 Aug 2022 12:01:57 GMT]]>Jeg er også med investorBava. Jeg er lang i aktien. Fornuftig pipeline

]]>https://dev.proinvestor.com/forum/post/8064958https://dev.proinvestor.com/forum/post/8064958Mon, 22 Aug 2022 12:01:57 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 22 Aug 2022 11:14:01 GMT]]>3 Biopharmas on Buyout Watch https://www.proinvestor.com/investornyt/869514/3-biopharmas-on-buyout-watch

]]>https://dev.proinvestor.com/forum/post/8064957https://dev.proinvestor.com/forum/post/8064957Mon, 22 Aug 2022 11:14:01 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 22 Aug 2022 11:02:38 GMT]]>@DevOp, så har jeg købt en lottokupon, nu må jeg læse lidt op lektion 😉

]]>https://dev.proinvestor.com/forum/post/8064956https://dev.proinvestor.com/forum/post/8064956Mon, 22 Aug 2022 11:02:38 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 22 Aug 2022 10:27:55 GMT]]>ExpreS2ion: Breast cancer HER2 vaccine i klinikken omkring 2023, blockbuster potentiale. Godt nok kun 1/3 af Covid vaccinen i størrelse, men 100% ejet af Expres2ion. Så jeg tænker at holde dem til efter både covid og breast cancer resultater, hvor sidstnævnte nok ikke lige lander indenfor 6-12 måneder.

]]>https://dev.proinvestor.com/forum/post/8064953https://dev.proinvestor.com/forum/post/8064953Mon, 22 Aug 2022 10:27:55 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 22 Aug 2022 07:17:49 GMT]]>Findes der ExpreS2ion Biotech Holding AB aktionærer her på ProInvestor? hvad tænker i om de kommende 6-12 måneder?

]]>https://dev.proinvestor.com/forum/post/8064967https://dev.proinvestor.com/forum/post/8064967Mon, 22 Aug 2022 07:17:49 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Thu, 18 Aug 2022 07:18:03 GMT]]>bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy

]]>https://dev.proinvestor.com/forum/post/8064952https://dev.proinvestor.com/forum/post/8064952Thu, 18 Aug 2022 07:18:03 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Tue, 16 Aug 2022 05:32:15 GMT]]>…stiger 15% på denne nyhed

]]>https://dev.proinvestor.com/forum/post/8064950https://dev.proinvestor.com/forum/post/8064950Tue, 16 Aug 2022 05:32:15 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Tue, 16 Aug 2022 05:31:50 GMT]]>Saniona.

]]>https://dev.proinvestor.com/forum/post/8064955https://dev.proinvestor.com/forum/post/8064955Tue, 16 Aug 2022 05:31:50 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Tue, 16 Aug 2022 05:31:44 GMT]]>https://news.saniona.com/news-releases/news-release-details/saniona-progresses-its-kv7-epilepsy-program-lead-optimization

]]>https://dev.proinvestor.com/forum/post/8064954https://dev.proinvestor.com/forum/post/8064954Tue, 16 Aug 2022 05:31:44 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 15 Aug 2022 09:34:45 GMT]]>Jeg tror dog BP vil være interesseret, da RPT193 er oral og indtil videre har de vist fin effekt i AD og en god bivirkningsprofil.

]]>https://dev.proinvestor.com/forum/post/8064960https://dev.proinvestor.com/forum/post/8064960Mon, 15 Aug 2022 09:34:45 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 15 Aug 2022 09:33:00 GMT]]>Som tidligere nævnt går de efter et selskab der vil udvikle RPT93 bredt og serielt, for ellers ønsker de at tage AD og astma indikationerne længere frem, før de laver en aftale. Deres CEO Brian Wong sagde tidligere, at baren var høj hvis de skulle have nogen ind nu.

]]>https://dev.proinvestor.com/forum/post/8064946https://dev.proinvestor.com/forum/post/8064946Mon, 15 Aug 2022 09:33:00 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 15 Aug 2022 09:30:10 GMT]]>https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-reports-second-quarter-2022-financial-results

]]>https://dev.proinvestor.com/forum/post/8064949https://dev.proinvestor.com/forum/post/8064949Mon, 15 Aug 2022 09:30:10 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 15 Aug 2022 09:30:07 GMT]]>De kom med regnskab i sidste uge og der var ikke meget info at hente - tillige er de ikke ret aktive hos diverse investeringshuse pt, så tænker
de har fokus på at skrue en fornuftig aftale sammen på RPT193.

]]>https://dev.proinvestor.com/forum/post/8064947https://dev.proinvestor.com/forum/post/8064947Mon, 15 Aug 2022 09:30:07 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Mon, 15 Aug 2022 09:27:54 GMT]]>Nogen der har kastet mønt efter RAPT Therapeutics - kursudviklingen er stærk for tiden og omsætningen også fin.

]]>https://dev.proinvestor.com/forum/post/8064948https://dev.proinvestor.com/forum/post/8064948Mon, 15 Aug 2022 09:27:54 GMT<![CDATA[Reply to Biotek-snakken — August 2022 on Sun, 14 Aug 2022 12:45:58 GMT]]>2 Tips for Investing in Biotech Stocks With High Growth Potential https://www.proinvestor.com/investornyt/866528/2-tips-for-investing-in-biotech-stocks-with-high-growth-potential

]]>https://dev.proinvestor.com/forum/post/8064945https://dev.proinvestor.com/forum/post/8064945Sun, 14 Aug 2022 12:45:58 GMT